Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Sponsored by Queen Mary University of London

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.

Target enrollment

Dec 2022

Start date

Oct 2027

Expected completion

Interventions / Treatments

Tyruko Injectable ProductPlacebo

Multiple Sclerosis

U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.

The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.